Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
90 results about "Integrin receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Integrin-like receptors (ILRs) are found in plants and carry unique functional properties similar to true integrin proteins. True homologs of integrins exist in mammals, invertebrates, and some fungi but not in plant cells. Mammalian integrins are heterodimer transmembrane proteins that play a large role bidirectional signal transduction.
Engineered anti-alpha V-integrin hybrid antibodies
ActiveUS8562986B2Reduce in quantityEliminate and reduce immune responseAntibody ingredientsImmunoglobulinsHeavy chainBinding site
Owner:MERCK PATENT GMBH
Delivery system for nucleic acids
Owner:THE SCRIPPS RES INST +1
Novel polypeptide modified tumor targeted liposome of targeted integrin receptor
InactiveCN103417480AIncrease intakeAntitumor effectMacromolecular non-active ingredientsHybrid peptidesTumor targetCholesterol
The invention provides a novel polypeptide modified tumor targeted liposome of a targeted integrin receptor. The novel polypeptide is mainly formed by covalent linkage of ring-shaped RGD and cell penetrating peptides, and not only has the selective targeting capability of an integrin receptor, but also can achieve mediated endocytosis; the liposome mainly comprises phospholipid, cholesterol, lipid-polyethyleneglycol and lipid-polyethyleneglycol-novel polypeptide ligand chimeric substance, and is a very potential tumor targeted treatment carrier.
Owner:SICHUAN UNIV
Integrin targeted synthetic ligands for diagnostic and therapeutic applications
ActiveUS8636977B2Organic active ingredientsPeptide/protein ingredientsCyclic peptideIntegrin targeting
Owner:BRACCO IMAGINIG SPA
Anti-alpha v immunoliposome compositions, methods and uses
InactiveUS20110268655A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsInternalizationTargeting ligands
An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.
Owner:CENTOCOR ORTHO BIOTECH
Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa
Owner:AFFIMED THERAPEUTICS AG
Bioactive stents for type II diabetics and methods for use thereof
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
Owner:MEDIVAS LLC
Engineered Anti-alpha v-integrin hybrid antibodies
ActiveUS20100254977A1Reduce in quantityEliminate and reduce immune responseAnimal cellsSugar derivativesHeavy chainBinding site
The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
Owner:MERCK PATENT GMBH
Agonists that enhance binding of integrin-expressing cells to integrin receptors
ActiveUS20130236434A1Enhance integrin-mediated bindingHigh retention rateBiocideCarbamic acid derivatives preparationAgonistTreated cell
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
Owner:TEXAS HEART INST
Polypeptide having high affinity with receptor of integrin alpha v beta3
The invention belongs to the fields of bioengineering pharmacy, protein polypeptide drugs and biomedical engineering and relates to a polypeptide having high affinity with a receptor of integrin alpha v beta3 and application of the polypeptide. The sequence of the polypeptide is Arg-Trp-Arg or Arg-Lys-Tyr. The polypeptide disclosed by the invention has higher affinity with the integrin alpha v beta3 than the traditional RGD (Arginine-Glycine-Aspartic acid) peptide and can be used in diagnosis and treatment of cancer.
Owner:CHINA PHARM UNIV
Double receptor identified serial cell-penetrating peptide modified tumor targeted nano drug delivery system
The invention provides a serial cell-penetrating peptide modified tumor targeted and tumor penetrated nano drug delivery system capable of simultaneously identifying an integrin receptor and a transmembrane protein receptor, wherein the serial cell-penetrating peptide is mainly formed by connecting a DGR polypeptide fragment covalently at the C-tail end of polyarginine of the cell-penetrating peptide. The polypeptide not only can selectively identify two highly expressed receptors on the surfaces of the tumor cells, but also can be efficiently mediated into the cells. The nano drug delivery system mainly consists of a nano carrier, a drug and a lipid-polyethylene glycol-serial cell-penetrating peptide ligand interstitial compound and is a potential tumor targeted treatment carrier.
Owner:SICHUAN UNIV
Integrin receptor inhibitors
Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to α4 integrin receptors and thereby inhibit binding of ligands for α4 integrins which is useful for prophylactic and / or therapeutic treatment of diseases and conditions associated with α4 integrins or their ligands.
Owner:GENENTECH INC
Chimeric vectors and their use for heterologous genes transfer
Owner:CONSORZIO INTERUNIVRIO PER LE BIOTECH
Integrin receptor target lipidosome drug carrier, preparation method and application thereof
The invention discloses an integrin receptor target lipidosome drug carrier and a preparation method thereof, as well as an application of the drug carrier in preparing antitumor lipidosome drug. Hexadecyl fatty chain is conjugated with RGD peptide segment and is hydrophobic-modified so as to synthesize hexadecyl and RGD peptide conjugate with amphipathy, namely, Arg-Gly-Asp-X-NH-C16H33, and X is selected from valine, serine or phenylalanine. The invention introduces fat-soluble antitumor drug into the conjugate with amphipathy to obtain the antitumor target lipidosome drug, the lipidosome system can increase the concentration of the antitumor drug at the target and can reduce toxic and side effects of the antitumor drug to the non-target part, thereby improving the treatment index of the drug. The invention evaluates the antitumor activity of taxol lipidosome by using a Holland sarcoma S180 mouse as a model, the result shows that the taxol lipidosome has more excellent antitumor activity than each control group.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Exosome carrier of target integrin alpha v beta 3 and preparation method and application of exosome carrier
ActiveCN109666695APromote apoptosisCo-loaded genes are goodOrganic active ingredientsSpecial deliveryWilms' tumorTumor cell apoptosis
The invention relates to the technical field of medicine, in particular to an exosome carrier of a target integrin alpha v beta 3 and a preparation method and application of the exosome carrier. Mononuclear suspension cells THP-1 are adopted and stimulated by PMA of the certain concentration to obtain the exosome carrier, the surface of an exosome after separating contains an RGD target molecule metalloprotease disintegrin family 15, and the target integrin receptor alpha v beta 3 can be obtained. The in-vitro releasing experiment shows that the prepared exosome can slowly release loaded chemotherapeutic medicine, and the better capacity of jointly loading genes and the chemotherapeutic medicine is achieved. In the tumor treatment process, the exosome can enhance the effects of cells of aspecificity target overexpression integrin alpha v beta 3 on tumor cells through the chemotherapeutic medicine or gene medicine, apoptosis of tumor cells is promoted, and therefore the exosome carrierforms a targeted and efficient low-toxicity bionic nanoscale delivery system of tumor treatment.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Combined drug-loading micelle of targeted integrin receptor and preparation method thereof
ActiveCN103800915AHigh drug loadingImprove therapeutic indexOrganic active ingredientsSolution deliveryMixed micelleArginine
The invention belongs to the technical field of biological medicines, and relates to a combined drug-dosing micelle of a targeted integrin receptor and a preparation method thereof. Pluronic COOH which is modified by a terminal carboxyl is synthesized, and RGD (arginine-glycine-aspartic acid) polypeptides are connected with carboxyl by amido bonds to obtain a RGD polypeptide-modified Pluronic copolymer (RGD-Pluronic); and after copolymerization of drug doxorubicin (DOX) and Pluronic, another drug PTX (paclitaxel) is coated and loaded by a thin-film hydration method to prepare a mixed micelle (RGD-FP-DP). According to the preparation method, drug loading capacity of the micelle can be improved, the drug concentration of anti-tumor drugs in a target site can be increased, accumulation of the anti-tumor drugs in a non target site can be reduced, and the therapeutic index of the drugs can be effectively improved.
Owner:FUDAN UNIV
Camptothecins Conjugated in Position 7 to Cyclic Peptides as Cytostatic Agents
Compounds of Formula (I) are described in which the R1 group is as defined in the specification and includes the condensation of the camptothecin molecule in position 7 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors αvβ3 and αvβ5 and with selective cytotoxic activity on human tumour cell lines at micromolar concentrations.
Owner:SIGMA TAU IND FARMACEUTICHE RIUNITE SPA +1
Targeted adhesion chitosan material and application thereof
ActiveCN101747451AEasy to separateReduce chemical toxicityGenetic material ingredientsPharmaceutical non-active ingredientsSolubilityCell adhesion
The invention relates to a targeted adhesion chitosan material and application thereof. Under the action of dual-functional (N-hydroxysuccinimide / azide) light-sensitive cross-linking agent, through grafting reaction by UV photochemical activation, cell adhesion peptide is grafted on the chitosan to obtain the safe (non-toxic and degradable) targeted adhesion chitosan material which is characterized in that the biocompatibility is good, the biological function is good and the dissolubility under faintly acid condition is obviously enhanced. Through self assembling method, the targeted adhesion chitosan material can form stable nano particles with grain size of 100mm-500mm and surface positive charge of 10mV-30mV and the stable nano particles can be used as the carriers of DNA (20bp-10kb) or RNA [dsRNA (500-700bp), small RNA (siRNA, microRNA or shRNA)] and other nucleic acid drugs. When the carried DNA or RNA is protected from being degraded by the corresponding enzyme, the carried DNA or RNA can target at the overexpressed integrin receptors on the surface of tumor cells, so cell transfection and release in cells are facilitated to cure tumors.
Owner:ZHANGJIAGANG IND TECH RES INST CO LTD DALIAN INST OF CHEM PHYSICS CHINESE ACADEMY OF SCI
Integrin receptor inhibitors
Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to α4 integrin receptors and thereby inhibit binding of ligands for α4 integrins which is useful for prophylactic and / or therapeutic treatment of diseases and conditions associated with α4 integrins or their ligands.
Owner:GENENTECH INC
Delivery system for nucleic acids
InactiveUS7025987B2Accelerated destructionOrganic active ingredientsBiocideAmphiphileIntegrin antagonist
αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Anti-Alpha V Immunoliposome Composition, Methods, and Uses
InactiveUS20090175784A1Inhibit growthPrevent proliferationBacteriaFermentationCytoplasmInternalization
An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.
Owner:CENTOCOR ORTHO BIOTECH
Integrin receptor alpha-v-beta-3 related 5-peptide
Owner:CHINA PHARM UNIV
Cyr61 compositions and methods
InactiveUS20090081228A1Promote growthImproving tissue graftingPeptide/protein ingredientsTissue cultureCell adhesionSignalling molecules
Polynucleotides encoding mammalian ECM signaling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signaling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signaling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signaling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signaling molecules. Further provided are methods for using mammalian ECM signaling molecules to screen for, and / or modulate, conditions and disorders associated with angiogenesis, chondrogenesis, and oncogenesis; ex vivo methods for using mammalian ECM signaling molecules to prepare blood products are also provided. Additionally, modulators, such as peptide modulators, of an ECM signaling molecule activity are provided. Further provided are methods for screening for modulators of a Cyr61 polypeptide-integrin receptor interaction, as well as methods of treating conditions and disorders associated with such an interaction.
Owner:MUNIN
Bioactive bracket for type II diabetics and methods for use thereof
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
Owner:MEDIVAS LLC
Peptide-Based Compounds
InactiveUS20090263320A1Useful in treatmentOrganic active ingredientsSenses disorderCrystallographyImaging agent
Owner:GE HEALTHCARE AS
Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents
Compounds of Formula (I) are describedin which the R1 group is as defined in the specification and includes the condensation of the camptothecin molecule in position 7 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors αvβ3 and αvβ5 and with selective cytotoxic activity on human tumour cell lines at micromolar concentrations.
Owner:SIGMA TAU IND FARMACEUTICHE RIUNITE SPA +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com